Latest Articles

Act Now for Your ACS Patients: Optimize Your ACS Pathway

Lp(a) as ASCVD risk factor

The role of the patient in Achieving LDL-C Target

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

EAS guidance regarding combining Lipid-modifying therapy

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Cardiovascular Disease

PCSK9i after hospital discharge for acute MI